1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

The purpose of this document is to update the “2014 AHA/ACC/HRS Guideline for the
Management of Patients With Atrial Fibrillation” S1. 3-1 (2014 AF Guideline) in areas for …

Background: Patients with end-stage kidney disease (ESKD) on dialysis were excluded from
clinical trials of direct oral anticoagulants for atrial fibrillation (AF). Recent data have raised …

Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …

Background Catheter ablation of atrial fibrillation is typically performed with uninterrupted
anticoagulation with warfarin or interrupted non–vitamin K antagonist oral anticoagulant …

Background An integrated care approach might be of benefit for clinical outcomes of patients
with atrial fibrillation (AF). This study evaluated whether compliance with the Atrial fibrillation …

Background: Lifelong oral anticoagulation, either with warfarin or a non–vitamin K
antagonist oral anticoagulant (NOAC), is indicated for stroke prevention in most patients with …

Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

Objective Since 2010, several non–vitamin K antagonist oral anticoagulants (NOACs) have
been brought to the US market, yet little is known regarding their evolving adoption for …

The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major
bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to …